Brain 17 Vienna

EGFR inhibitors

• Activating EGFR mutations particularly commmon in adenocarcinomas of the lung • EGFR mutations may be overrepresented in brain mets of lung cancer patients • Clinical activity of EGFR inhibitors in patients with activating EGFR mutations has been shown in several large trials

• Modest BBB penetration of EGFR inhibitors

Lynch et al. N Engl J Med 2004 Paez et al. Science 2004 Matsumoto et al. Int J Cancer 2006 Park et al. Lung Cancer 2012 Maemondo et al. N Engl J Med 2010 Rosell et al. Lancet Oncol 2012